



REVIVE Global Newsletter

Participating Countries: 14
Participating sites: 57
Enrolling countries: 6
Activated sites: 18
Participant enrollment: 693

From the Project Office:

We are pleased to announce that since our last newsletter in April, we have welcomed new sites from Botswana, Ivory Coast, and Nigeria. We extend our heartfelt gratitude to everyone who has tirelessly contributed to this achievement!



Significant progress has been made with ethics and regulatory approval process across the remaining 8 countries. We look forward to seeing the further results of your efforts!

Reminders:

Ensuring medical oversight of research participants is a key responsibility for investigators under Good Clinical Practice (GCP) guidelines. It is essential that a site Principal Investigator (PI) or Co-Investigator (Co-I) is actively involved in the decision-making process regarding the review of eligibility criteria, as well as in assessing any outcome or safety events that occur. PI or Co-I must oversee the participant data entered in the DfExplore (EDC) system. It is imperative that *electronic signatures* are promptly provided on all applicable Case Report Forms (CRFs).

Encourage participants to adhere to the dosing schedule outlined in the protocol. Depending on participant compliance, some tablets may remain at the end of the 28 day treatment period. Instruct participants to return their study drug blister pack when they come for the Week 4 in-person follow-up visit. During the Week 4 follow-up, please confirm the date of the last dose taken. Any remaining study drugs should be disposed of in accordance with local regulations.

For all eligible participants, please ensure a copy of the CD4 test result and documentation of HIV infection is saved in the participant binder as *source documentation*. If a printout of concomitant medication information is available, include a copy in the participant binder as well for each follow-up visit. If a printout is not available, note in the binder how the information was obtained.



Vanguard Target Achieved:

We reached a major milestone in June hitting our Vanguard recruitment target of **600** participants. We look forward to achieving our ultimate goal of **8,000** participants. We thank REVIVE National Leaders, Site PIs and Site teams for your dedication and support!

REVIVE Featured:

REVIVE trial was featured in the WHO Advanced HIV disease research landscape document in the Severe Bacterial Infections Section. *“A single randomized controlled trial is examining the role of azithromycin prophylaxis in advanced HIV disease. The REVIVE Trial plans to enroll 8000 participants, focusing on outpatients without evidence of a severe opportunistic infection or acute illness. The outcomes are hospitalization and all-cause mortality over the first 24 weeks after randomization.”* Key details of the trial were also shared.

REVIVE Monthly Seminars:

Monday, 12 August 2024 17H00 South African Standard Time	Dr John Eikelboom PHRI, Canada	Big Simple Trials
Wednesday, 25 September 2024 15H00 South African Standard Time	Dr Suleiman Lakoh / Dr Daniel Sesay Sierra Leone	HIV in Sierra Leone: epidemiology and clinical issues.
Wednesday, 30 October 2024 15H00 South African Standard Time	Dr Felix Dube South Africa	Pneumococcal colonisation dynamics in health and disease: Tales from an African birth cohort
Tuesday, 19 November 2024 15H00 South African Standard Time	Dr Bianca Sossen South Africa	TB diagnostics in HIV-associated TB

other subjects of interest to REVIVE study network. The first seminar, held on May 20th, focused on *Cryptococcal Meningitis and Antigenemia: Diagnosis, Prevention, and Treatment*. It was presented by Dr.

Conrad Muzoora, Sen. Lecturer, Internal Medicine, Mbarara University (NL, Uganda). **July** seminar will be on *HIV Associated Pneumocystis Pneumonia*, presented by Dr Trevor Mnguni, Head of Internal Medicine at Khayelitsha District Hospital, Cape Town, South Africa.



Newsletter (Page 2)

Country	Regulatory Status	Sites			Randomiza-tions	
		Planned	Activated	Enrolling	Last 30 days	Total
 South Africa	Approved	17	5	4	1	229
 Sierra Leone	Approved	3	2	2	28	250
 Uganda	Approved	5	1	1	13	126
 Nigeria	Approved	11	8	5	18	85
 Botswana	Approved	1	1	0	0	0
 Ivory Coast	Approved	3	1	1	0	3
 Republic of Congo	Approved	1				
 Malawi	Pending	1				
 Ghana	Pending	3				
 Zambia	Pending	3				
 Ethiopia	Pending	4				
 Mozambique	Pending	1				
 Rwanda	Pending	1				
 Tanzania	Pending	3				
Total		57	18	13	60	693

Newsletter (Page 3)

Site Spotlight: Connaught Hospital, Freetown, Sierra Leone: Dr. Daniel Sesay (PI, Site 351)



Daniel was born on March 15, 1990, in the eastern district of Kono, Sierra Leone, to Sierra Leonean parents. His early life was marked by the turbulence of the civil war, prompting his family to relocate to Freetown when he was just two years old. This early displacement undoubtedly shaped his resilience and adaptability, qualities that would serve him well in his future medical career.

Daniel's academic journey led him to the College of Medicine and Allied Health Science at the University of Sierra Leone, where he graduated in 2018 with a Bachelor of Medicine, Bachelor of Surgery (MB, ChB) degree. His commitment to furthering his medical expertise saw him pursuing residency training in Internal Medicine with the West African College of Physicians at the University of Sierra Leone Teaching Hospital Complex. Simultaneously, he is working towards a Master of Public Health (MPH) degree from Texila American University.

Since 2020, Daniel has been dedicated to working in the HIV unit at Connaught Hospital. His

role involves providing both outpatient and inpatient services to HIV patients, a responsibility he has embraced with unwavering dedication. His work in this unit is not just a job; it is a calling driven by a profound desire to alleviate the suffering of those with advanced HIV disease.

Daniel's decision to join the Revive trial underscores his commitment to this cause. The trial aims to improve the lives of patients with advanced HIV disease, a mission that resonates deeply with him. Educating participants about the trial's significance and the potential to prevent deaths and alleviate suffering serves as his primary motivational factor. He is passionate about ensuring that participants understand the trial's importance and the positive impact it could have on their lives.

Beyond his professional life, Daniel enjoys listening to music and watching football. These hobbies provide him with much-needed relaxation and balance amidst the demanding nature of his work.

Daniel's journey from a war-affected child in Kono to a dedicated medical professional in Freetown is a testament to his resilience, commitment, and passion for medicine. His work at Connaught Hospital and involvement in the REVIVE trial highlight his dedication to improving the lives of HIV patients and his broader goal of contributing to public health. Daniel's story is one of perseverance and dedication, inspiring those around him and promising a brighter future for many patients.